By Fineline Cube Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced its participation in a Series B financing round for Suzhou Xingyao Kunze Biopharmaceutical Co., Ltd. (Hepa Thera), contributing RMB 220 million (USD 32.4 million). Following the transaction, Fosun Pharma will hold 20.8709% of Hepa Thera, becoming the liver disease specialist’s second largest shareholder.
Investment Overview
| Parameter | Detail |
|---|---|
| Investor | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) |
| Portfolio Company | Suzhou Xingyao Kunze Biopharmaceutical Co., Ltd. (Hepa Thera) |
| Investment Amount | RMB 220 million (USD 32.4 million) |
| Post-Investment Stake | 20.8709% |
| Investor Position | Second largest shareholder |
| Incubation Relationship | Hepa Thera incubated through Fosun Health Capital New Drug Fund |
Hepa Thera Pipeline Portfolio
HT-101 – siRNA Therapeutic for Chronic Hepatitis B
- Molecule Type: GalNAc-conjugated siRNA innovative drug
- Target Specificity: High liver targeting specificity
- Mechanism of Action: Silences HBV mRNA to block synthesis of multiple viral proteins at source
- Development Stage: Phase II clinical trials in China for chronic hepatitis B virus (cHBV) infection
- Therapeutic Advantage: Addresses root cause of viral replication rather than downstream effects
HT-102 – Neutralizing Antibody for Chronic Hepatitis B
- Molecule Type: Fully human monoclonal antibody
- Target: HBsAg (hepatitis B surface antigen)
- Mechanism of Action:
- Prevents HBV reinfection
- Clears HBsAg-containing subviral particles from circulation
- Reduces subviral particle-mediated immunosuppression
- Development Stage: Phase II studies in cHBV in China
Combination Therapy Strategy
- Rationale: Dual targeting of HBsAg in both hepatocytes (HT-101) and peripheral blood (HT-102)
- Mechanistic Synergy: Complementary mechanisms addressing different aspects of HBV lifecycle
- Clinical Development: Combination regimen being evaluated in Phase II cHBV study in China
- Therapeutic Goal: Functional cure of chronic hepatitis B through comprehensive viral suppression and immune restoration
Strategic Rationale & Market Context
Fosun Pharma Investment Thesis
- Vertical Integration: Strengthens Fosun’s position in hepatology therapeutics
- Portfolio Diversification: Adds innovative modalities (siRNA + monoclonal antibody) to existing pipeline
- Incubation Success: Validates Fosun Health Capital New Drug Fund’s biotech development model
- Commercial Optionality: Potential future acquisition or partnership rights
Hepatitis B Market Opportunity
- Global Burden: 296 million people chronically infected with HBV worldwide
- China Prevalence: Approximately 70 million chronic HBV carriers
- Treatment Gap: Current therapies rarely achieve functional cure; significant unmet need for novel approaches
- Market Size: $5+ billion global HBV therapeutics market projected to grow with curative therapies
Competitive Landscape
- Innovation Leadership: Combination of siRNA and neutralizing antibody represents cutting-edge approach
- GalNAc Technology: Leverages proven liver-targeting platform for enhanced efficacy and reduced systemic exposure
- Functional Cure Focus: Aligns with industry shift toward curative rather than suppressive HBV therapies
Development Timeline & Next Steps
- Current Status: Both HT-101 and HT-102 in Phase II monotherapy and combination studies
- Data Readouts: Expected 2027-2028 timeframe
- Regulatory Pathway: Potential breakthrough therapy designation given novel mechanism and high unmet need
- International Expansion: Global development possible following Chinese clinical validation
Forward-Looking Statements
This brief contains forward-looking statements regarding investment outcomes, clinical development timelines, and market expectations for Hepa Thera’s pipeline. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market access challenges.-Fineline Info & Tech